Cipla, a leading drug maker, received a warning letter from the US drug regulator for its Goa manufacturing facility.

In a regulatory filing, the company said that it has received a warning letter from the United States Food and Drug Administration (USFDA) for its Goa manufacturing facility that was inspected from September 16-27, 2019.

''The Company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations,'' the company statement said.

Shares of the company declined Rs 3.85, or 0.91%, to trade at Rs 421.50. The total volume of shares traded was 116,165 at the BSE (2.22 p.m., Wednesday).